drugset / Trial / NCT00433693

Correction Study of R744 in Renal Anemia Patients on Hemodialysis

NCT00433693

Phase 3 Completed 50 enrolled Chugai Pharmaceutical
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will assess the efficacy and safety of intravenous R744 in renal anemia patients on hemodialysis.

Timeline

Start
2007-02
Primary completion
2008-03
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject methoxy polyethylene glycol-epoetin beta Protein / enzyme biologic 25 ug Intravenous
Subject methoxy polyethylene glycol-epoetin beta Protein / enzyme biologic 300 ug Intravenous

Indications

No indication recorded.